Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

In Support of National Pet Choking Prevention Day (June 22) Bow Wow Labs® Champions This Important Cause by Offering a Giveaway During the Month of June

Leave a comment



NOVATO, Calif. (PRWEB)

Tragically, there are over 200,000 pet choking incidents in the United States every year, not only resulting in millions of dollars in veterinarian fees, but more importantly, also costing pet-parents and veterinary professionals an immeasurable and irreversible physical and emotional toll.

Inspired to bring national attention to how scary, how common and how avoidable pet choking really is, Bow Wow Labs, Inc. is championing this education and awareness campaign for pet safety by officially registering June 22nd as National Pet Choking Prevention Day and announcing a national giveaway in June to match 3 lucky dog lovers with their life-protecting Bow Wow Buddy Starter Kits & 2 Month Subscription.

Inventors of the life-protecting Bow Wow Buddy™ safety device, Bow Wow Labs shares the facts to focus on prevention through education and engage a global community of passionate pet-parents and pet-lovers around the world that share their dedication to keep pets safe, healthy and happy.

Giveaway – Dates and Rules:

Giveaway eligibility starts June 1st at 12:01 AM Eastern Time (EST) and goes through June 22nd at 11:59 AM EST. Bow Wow Labs will announce 3 lucky winners on June 22rd at 12pm EST. Eligible winners must reside in the U.S. only.

To enter to win:

1. Find @BowWowLabs on Instagram: http://www.instagram.com/bowwowlabs

2. Click on the link in Bow Wow Labs’ Instagram bio

3. Click “Enter Giveaway” and enter an active email address *This email address will be how winners are contacted.

4. Follow @BowWowLabs on Instagram while you’re there!

Teaming up with renowned veterinarian and spokesperson Dr. Judy Morgan, National Pet Choking Prevention Day will be recognized for the first time on June 22, 2023 with a simple mission of “Target: Zero”. Spreading education to pet-parents all over the globe about the everyday pet choking hazards around your home. The National Pet Choking Prevention Day campaign shares the shocking statistics of how common (and avoidable) pet choking is, but most importantly, it shares the simple yet important ways we can come together to help eliminate common risks from toys, chews, and more for our beloved pets.

Sadly, pet choking tragedies (or near-tragedies when the pet does survive) cause panic, fear and anxiety to pets, pet-parents and veterinary professionals worldwide that try to save their lives, but retailers and pet-parents alike must come together to educate and promote prevention.

As we approach, National Pet Choking Prevention Day, here are 5 everyday choking hazards for both dogs and cats that are commonly found in and around the home:

CATS:

  • String

  • Window Blind Cords

  • Fishing Pole/Wand Type Toys

  • Plastic

  • Rubber Bands & Hair Ties

DOGS:

  • Balls

  • Sticks

  • Chew Toys

  • Bully Sticks, Treats & Long Term Chews

  • Food Packaging & Trash

At the forefront of prevention is an affordable, simple to use product that can save more pets lives–the Bow Wow Buddy safety device is life-protecting, veterinarian-approved and dog-loved. Each Bow Wow Buddy device tightly secures bully sticks and other long-term chews, helping to prevent dogs from choking on that last small bit while at the same time reducing the potential risk of obstruction on the tail-end of the treat.

For more information on National Pet Choking Prevention Day and be part of change, please visit http://www.nationalpetchokingpreventionday.com. For more information about Bow Wow Labs and their unwavering commitment to saving more pets’ lives, the award-winning product-innovations, and more, please visit http://www.bowwowlabs.com.

###

About Bow Wow Labs: Bow Wow Labs, Inc. (BWL) are makers of innovative products that help to keep dogs safe, healthy, and happy. BWL is best-known for the life-protecting Bow Wow Buddy along with their line of Safe Fit™ Bully Sticks, which have had great success since launching in 2018. Safe Fit™ Bully Sticks are made from fresh, 100% grass-fed cattle, free of chemicals and hormones. With a growing line of nutritious dog treats and chews, BWL has many more new products and innovation on the horizon! Learn more at: https://bowwowlabs.com/.

LinkedIn: https://www.linkedin.com/company/bow-wow-labs

Twitter: https://twitter.com/bowwowlabs?lang=en

Instagram: https://www.instagram.com/bowwowlabs/?hl=en

Facebook: https://www.facebook.com/bowwowlabs

YouTube: https://www.youtube.com/channel/UCk-MXoO3hzQr7Yxn37W7rMw

TikTok: https://www.tiktok.com/@bowwowlabs

Share article on social media or email:



Health

Dental Graduates Eager To Start Their Careers Can’t Skimp on Ergonomics

Leave a comment


News Image

To enjoy a long career in dentistry, proper ergonomics is one of the first things to remember and the last thing to forget


CLEARWATER, Fla. (PRWEB)

The demand for dental hygienists is predicted to increase by 9% from 2021 to 2031, faster than the average of any other occupation, with 16,300 job openings projected each coming year.(1) The demand for dentists is expected to grow by 6% during the same timeframe, with a forecast of 5,100 job openings annually.(2) Recent graduates in the dental profession are typically not thinking about their retirement; however, as dental professionals, they are at a much higher risk of developing musculoskeletal disorders (MSDs) that could cut their careers short. MSDs are injuries to the soft tissues affecting muscles, nerves, tendons, joints, and cartilage in the upper and lower limbs, neck, and lower back. MSDs can result from repetitive motion, exertion, vibration, and awkward positioning. Whether chronic or acute, exposure to these factors can be debilitating.(3) Adrian LaTrace, CEO of Boyd Industries, observes, “The first day at work for any new graduate can be both exciting and terrifying. For new arrivals to the dental field, trying to remember all those years of academic instruction and its precise practical applications can be a bit challenging at first. However, to enjoy a long career in dentistry, proper ergonomics is one of the first things to remember and the last thing to forget.”

Work-related MSDs are an all-too-common occupational hazard throughout the healthcare industry. A research study of a cross-section of health professionals, including surgeons, physicians, and dentists, discovered that dentists had the highest rate of musculoskeletal pain at 61%, with 60% of dentists experiencing MSDs in multiple sites.(4) Research for risk factors among dental practitioners discovered that dental hygienists experience even higher rates of MSDs of the shoulders and neck than dentists.(5) Another study highlighted the prevalence of MSDs among dental hygienists while still in school, emphasizing the need for proper ergonomic training and intervention before the commencement of fieldwork.(6) If MSDs aren’t treated early and effectively, they can lead to permanent disability and adversely affect mental health.(7)

The number one reason for early retirement among dentists is musculoskeletal disorders. Mitigating the risks of all patient-centered occupations in dentistry requires a deep dive into the ergonomics of dentistry. A veteran clinical dental hygienist advises developing good ergonomic habits and techniques from the very beginning. Dental professionals should focus on proper body mechanics, optimal instrumentation stroke, and mastering indirect vision — being able to visualize each area while keeping the neck and back straight. One MSD risk factor to watch out for is correct patient seating positions that could be too low or too high.

There are preventative tools available that include ergonomically-designed sharp instruments, magnification loupes, and operator seating.(8)

The equipment in the treatment area — patient chair, lighting, cabinetry, and auxiliary tools — should be flexible and conducive to good working postures with easy access to essential dental instruments and should be adaptable to specific dental practices, clinical procedures, and patient types.(9)

Boyd Industries is a pioneer in the design and manufacture of state-of-the-art dental and medical operatory equipment. Renowned among dental specialty practices and ENT specialists, Boyd’s reputation is built on their expert craftsmanship, ergonomic design, proven durability, and reliability. From dental exam, treatment, and surgery chairs to delivery systems, exam lighting, custom clinical cabinetry, operator seating, and other office accessories, Boyd’s line of products prioritizes dependable, ergonomic, and aesthetically pleasing design that enables dental professionals to deliver the highest-quality patient care with comfort and convenience.

LaTrace remarks, “As they say, an ounce of prevention is worth a pound of cure. Recent graduates just entering the dentistry field are particularly vulnerable if they forego proper body mechanics in an effort to prove themselves early on as capable and confident. Like professional athletes, dental professionals need to protect themselves against a career-ending injury.”

Built to last. Built for you. Built by Boyd.

About Boyd Industries

For 65 years, Boyd Industries has been the innovative market leader in the design and manufacture of dental and medical operatory equipment. Their high-quality and reliable equipment has been the choice of dental specialty practices and dental surgery offices. The rapidly expanding Ear, Nose, and Throat market now seeks its reputation for quality and innovation. Boyd equipment is specifically designed to provide maximum practice productivity while incorporating ergonomic characteristics for the doctor, staff, and patient. As an original equipment manufacturer, they use a vertically integrated approach to ensure their process meets high-quality standards. This approach allows Boyd to control each step of component fabrication and product assembly. Boyd’s products include a full line of dental exam, treatment, and surgical chairs, dental delivery systems, LED exam and surgical lighting, custom sterilization and storage cabinetry, and doctor or assistant seating. Boyd was named the Senate Small Business of the Week in November 2020 and is a ten-time winner of the Townie Choice Award for excellence in orthodontic operatory equipment. Boyd Industries is an FDA-registered manufacturer. Built to last. Built for you. Built by Boyd. http://www.boydindustries.com/.

References:

1. U.S. Bureau of Labor Statistics. (2022, September 8). Dental hygienists : Occupational outlook handbook. U.S. Bureau of Labor Statistics. bls.gov/ooh/healthcare/dental-hygienists.htm

2. U.S. Bureau of Labor Statistics. (2023, May 15). Dentists : Occupational Outlook Handbook. U.S. Bureau of Labor Statistics. bls.gov/ooh/healthcare/dentists.htm

3. Centers for Disease Control and Prevention. (2022, March 21). Musculoskeletal health program. Centers for Disease Control and Prevention. cdc.gov/niosh/programs/msd/default.html#:~:text=Description,limbs%2C%20neck%20and%20lower%20back

4. K;, R. T. (n.d.). Prevalence of work related musculoskeletal disorders among physicians, surgeons and Dentists: A comparative study. Annals of medical and health sciences research. pubmed.ncbi.nlm.nih.gov/25221708/

5. J;, M. T. H. (n.d.). Musculoskeletal disorders of the neck and shoulder in the dental professions. Work (Reading, Mass.). pubmed.ncbi.nlm.nih.gov/20448321/

6. D;, N. S. S. (n.d.). Musculoskeletal disorders among dental hygienist and students of Dental Hygiene. International journal of dental hygiene. pubmed.ncbi.nlm.nih.gov/32012436/

7. Hugues, J. C. O. (2023, January 13). The importance of ergonomics in dentistry. Decisions in Dentistry. decisionsindentistry.com/article/importance-ergonomics-dentistry/

8. National Board Dental Hygiene Examination 2021 guideline updates. (n.d.). dentistryiq.com/dental-hygiene/student-hygiene/article/14196267/national-board-dental-hygiene-examination-2021-guideline-updates

9. Gupta, A., Bhat, M., Mohammed, T., Bansal, N., Gupta, G. (2014, January). Ergonomics in Dentistry. International journal of clinical pediatric dentistry. ncbi.nlm.nih.gov/pmc/articles/PMC4144062/

Health

Ajinomoto Integrates R&D Sites in Japan and Korea with Genedata Bioprocess

Leave a comment


News Image

After the successful deployment in Japan, we have now expanded the use of Genedata Bioprocess to our Korea-based teams to facilitate cross-site projects, resulting in significantly more efficient operations in our joint projects. Hiroyuki Mise, General Manager of Biopharma Solutions at Ajinomoto


BASEL, Switzerland and TOKYO (PRWEB)

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, and Ajinomoto, a leading multinational supplier of cell culture media as well as development and manufacturing services (CDMO), today announced that Ajinomoto has successfully rolled out Genedata Bioprocess® to its Korean sites, Ajinomoto Genexine, in line with Ajinomoto’s transformational R&D digitalization strategy.

“Genedata Bioprocess has been quickly adopted by our Japanese teams to streamline and accelerate our media development activities,” said Hiroyuki Mise, General Manager of Biopharma Solutions Group, Amino Acids Department of Ajinomoto. “The platform integrates with our existing laboratory instrumentation, allowing us to evaluate huge volumes of cell culture media development data at a level of complexity that was previously unimaginable. After the successful deployment in Japan, we have now expanded the use of Genedata Bioprocess to our Korea-based teams to facilitate cross-site projects, resulting in significantly more efficient operations in our joint projects. At the same time, we are preparing for further expansion to our development site in China. Genedata allows us to accelerate cell culture media development so that our biopharma partners can develop novel innovative treatments and vaccines faster and at a lower cost.”

Ajinomoto uses Genedata Bioprocess as their central data backbone to streamline cell culture media development and production operations, including in regulated environments. A chemically defined cell culture medium typically contains dozens of components, the exact amounts of which must be precisely evaluated to improve expression yields and quality of biotherapeutic drugs. Media optimization is essential for the efficient production of modern biological medicines, for example immunotherapies, vaccines, stem cells, and other therapeutics. Defined cell culture media are extremely complex to develop and manufacture, with strict requirements to ensure product quality. Ajinomoto Genexine is known for their flagship products CELLiST™, high-performance media that are chemically defined and free from any animal-derived ingredients.

Genedata Bioprocess is a purpose-built digital platform enabling the end-to-end tracking and analysis of complex cell culture media compositions, including process parameters such as cell growth, together with product analytics and quality data. All information across Ajinomoto’s groups in Korea and Japan can now be traced and related in one central platform that ensures data integrity and compliance. Genedata Bioprocess is an integral part of Ajinomoto’s digitalization strategy, which utilizes automation, AI/ML, and Genedata’s advanced data infrastructure to maximize business value for custom media development projects and CDMO services.

“I am delighted to see that Ajinomoto is expanding the usage of Genedata Bioprocess across its Asian development and manufacturing sites, which is how we envision our platform to be used,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Since the Genedata Biopharma Platform is built on a scalable architecture, it is easy to distribute the management and analysis of big data across multiple sites and set ups. Our mission at Genedata is to accelerate biopharma R&D, and this is a great example of what can be achieved as the industry transitions to biopharma 4.0.”

About Ajinomoto

The Ajinomoto Group, unlocking the power of amino acids, aims to resolve food and health issues associated with dietary habits and aging, and contribute to greater wellness for people worldwide. Based on the corporate message “Eat Well, Live Well.”, we have been scientifically pursuing the possibilities of amino acids to aim for future growth by creating new value through sustainable and innovative solutions for communities and society. The Ajinomoto Group has offices in 36 countries and regions, and sells products in more than 130 countries and regions. In fiscal 2021, sales were 1.1493 trillion yen (9.6 billion U.S. dollars).

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com

LinkedIn | Twitter | YouTube

________________________________________

Contact

Allison Kurz

Genedata

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



Health

Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities

Leave a comment


Since its launch, we have been able to demonstrate how beneficial the OneBio integrated biologics development solution can be to sponsors, saving them time on managing multiple partners, and handoffs between companies.


SOMERSET, N.J. (PRWEB)

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA. The launch of the expanded offering will coincide with Catalent exhibiting at the BIO International Convention (booth 785), which takes place at the Boston Convention & Exhibition Center, from June 5-8, 2023.

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch. Under the newly expanded OneBio offering, customers will continue to benefit from an integrated contract and proposal, harmonized project management, a global development and manufacturing network, and diverse expertise, now across biologic modalities and service offerings.

“Since its launch, we have been able to demonstrate how beneficial the OneBio integrated biologics development solution can be to sponsors, saving them time on managing multiple partners, and handoffs between companies,” said Karen Flynn, Catalent’s Interim President, Division Head for BioModalities (Cell, Gene and Protein Therapies). “By expanding these services across multiple biologic therapies, Catalent is offering customers the opportunity to leverage its end-to-end capabilities in these areas and accelerate their programs to the clinic and beyond, mitigating potential risks and delays by providing planning efficiencies, an integrated contract, streamlined project management support, and harmonized quality systems.”

And for early-stage customers that need to develop and/or optimize their process towards GMP manufacturing, Catalent’s OneBio offering will include multi-modality, turn-key platforms aimed to provide speed to clinical trial supply under the UpTempoSM brand.

At the BIO International Convention, Carey Connolly, Ph.D., Catalent’s Senior Director, Process Development, will present ‘One-Stop Integrated Viral Vector Platform for Speed to Clinic’ on Tuesday, June 5, from 11 a.m. – 11:20 a.m. at the BioProcess International Theater. In her talk, Dr. Connolly will detail the integrated services within the UpTempo AAV development platform and the use of standardized protocols for cell culture, transfection, and downstream purification to save time, as well as the advantages it now has with an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to support a robust supply chain. Originally launched in 2022, the UpTempo AAV platform was expanded in March of 2023 to include Catalent’s own HEK293 producer cell line and off-the-shelf plasmids, including pHelper and rep/cap. Additional UpTempo platforms will follow for other modalities.

Catalent experts will be available to discuss other recent advancements across the Biologics segment, including high-speed syringe filling line investments at its sites in Anagni, Italy, and Bloomington, Indiana. In addition, Catalent Biologics’ European drug product network also recently saw the completion of upgrades to its site in Limoges, France, making it the company’s European center-of-excellence for early-phase clinical and small-scale commercial biologics formulation development and drug product fill/finish.

To find out more about Catalent’s activities at BIO, visit https://www.catalent.com/events/2023-bio-international-convention/ and to find out more about OneBio Suite and the UpTempo platform, visit https://biologics.catalent.com/.

About Catalent Biologics 

For nearly three decades, Catalent Biologics has built capabilities and expertise in development, manufacturing, and analytical services, now spanning new biological entities, biosimilars, plasmid DNA, cell and gene therapies, vaccines, sterile injectables, mRNA, and antibody-drug conjugates. It has developed processes for hundreds of biologic products, with more than 50 commercially approved products that have employed Catalent Biologics’ manufacturing and packaging capabilities as well as 20 approved/authorized biotherapeutics that have leveraged GPEx® cell line development technology.

Using advanced technologies and tailored solutions from clinical to commercial supply, Catalent brings better biologic and advanced treatments to patients, faster.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Health

Barriers and Opportunities for Acceleration, Upcoming Webinar Hosted by Xtalks

Leave a comment


In this webinar, the featured speakers will dive into the current and future state of histopathology and histology R&D.


TORONTO (PRWEB)

Digital pathology has been instrumental in accelerating preclinical R&D workflows to maximize efficiency and quality gains in routine operations, streamline collaboration and improve the reproducibility of results. In this webinar, the featured speakers will dive into the current and future state of histopathology and histology R&D.

During this engaging webinar, attendees will explore: the journey of digital pathology and artificial intelligence (AI) adoption for histology and histopathology R&D; And key considerations and drivers for digital pathology technology investments to help drive therapeutic innovation.

Join this webinar to explore the transformative impact of digital pathology and AI in preclinical R&D services.

Join Richard Bouffard, Director of Histology Lab, Virscio; Jennifer A. Cann, DVM, PhD, DACVP, Director of Pathology, Virscio; Golnaz Jalalahmadi, PhD, Image Analysis Research Scientist, Virscio; and Nathan Buchbinder, Co-Founder & Chief Product Officer, Proscia, for the live webinar on Tuesday, June 20, 2023, at 12pm EDT (9am PDT / 5pm BST).

For more information, or to register for this event, visit Digital Pathology in Preclinical R&D Services: Barriers and Opportunities for Acceleration.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Health

Olaris, Inc. debuts novel global QqQ LC mass spectrometry panel for clinical metabolomics applications at the American Society for Mass Spectrometry 2023 Meeting

Leave a comment


Olaris offers an end-to-end solution for biomarker discovery for internal discovery efforts and as an offering to our strategic partners.


FRAMINGHAM, Mass. (PRWEB)

Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company’s research on developing a triple-quadrupole (QqQ) mass spectrometry (MS) platform for clinical metabolomics applications has been selected for a poster presentation on June 5th at the upcoming American Society for Mass Spectrometry (ASMS) 2023 Annual Meeting, to be held June 4th-8th in Houston, TX.

“The new QqQ technology will expand our ability to detect clinically impactful changes in metabolites. Coupled with our CEREBRO machine learning platform, Olaris offers an end-to-end solution for biomarker discovery for internal discovery efforts and as an offering to our strategic partners.” said Dr. Elizabeth O’Day, CEO and Founder of Olaris.

Metabolites, small molecules involved in generating energy and maintaining our bodies, are altered with disease status and treatment response and therefore provide the most useful biomarkers for real-time measurements of clinical outcomes in biomedical and pharmaceutical research. Yet due to challenges with analytical measurements and reproducibility concerns, metabolomics has yet to reach its full potential in diagnostic and drug development. With its pioneering nuclear magnetic resonance (NMR) and now MS capabilities, Olaris is set to change this. The new QqQ MS platform is highly standardized, providing fidelity across batches, requires minimal sample volume, and enables accurate and reproducible measurements for +370 metabolites that span across biological pathways.

“Until now, in clinical metabolomics there was a tradeoff between measuring many hundreds of metabolites with limited accuracy and reproducibility or measuring highly accurate concentrations of only a limited set of metabolites. Olaris’ new MS method, combined with our existing NMR platform, eliminates this tradeoff, providing broad coverage of the metabolome, accuracy, and reproducibility at scale,” said Dr. Jurre Kamphorst, VP of MS Technology and Biomarkers at Olaris, who will present the research poster at ASMS.

For more information on the ASMS meeting or to view the Olaris presentation during the conference, visit http://www.asms.org. The presentation will be made available on Olaris’ website at http://www.myolaris.com/news following the conference.

About Olaris

Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline of myOLARIS™ precision diagnostics.

To learn more, visit https://www.myolaris.com/

Share article on social media or email:

Health

Olaris, Inc. to present data on metabolomic changes observed during DCD heart perfusion prior to successful transplant at the American Transplant Congress 2023 Meeting

Leave a comment


We believe that this is another example of how metabolomics coupled with the Olaris CEREBRO platform can be used to benefit patients, expand access to lifesaving treatments, and allow for better treatment decisions and outcomes.


FRAMINGHAM, Mass. (PRWEB)

Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company’s study on the metabolic changes occurring in donor hearts after Donation after Circulatory Death (DCD) heart transplant has been selected for a poster presentation on June 5th at the upcoming American Transplant Congress (ATC) 2023 Annual Meeting, to be held June 3rd-7th in San Diego, CA.

The ATC 2023 presentation will describe data from a multi-year collaboration between Olaris and an elite team of heart transplant surgeons and researchers at Massachusetts General Hospital, including Drs. Seyed Alireza Rabi, and Asishana Osho. The collaboration was formed with the goal of identifying biomarkers of heart damage due to ischemia and reperfusion during DCD heart transplant. DCD followed by ex vivo machine perfusion, in which organs are procured following circulatory death and placed on a machine to maintain viable status before transplant, represents a new method in heart transplant. Currently, over 3,000 Americans on the heart transplant waiting list each year are unable to access life-saving transplants due to a shortage in donor organs; using DCD for heart transplant has the potential to increase the number of available organs by over 30%, but improved measurements of heart quality are needed to improve DCD outcomes.

“Discovering biomarkers to aid us in maximizing the identification of appropriate hearts for transplant will be crucial to allow DCD to reach its full potential. The research that is ongoing at MGH and Olaris represents an exciting step forward in that direction,” said Dr. David D’Alessandro, the Surgical Director of Heart Transplantation and Ventricular Assist Devices at MGH.

To better understand the changes occurring in the heart during DCD transplant, Olaris’ researchers examined changes in metabolites in 19 hearts during the DCD process, comparing metabolite levels after heart procurement to those after hours of machine perfusion. They found that several metabolites were consistently altered over time, reflecting metabolic reprogramming in the DCD hearts during machine perfusion. The results of the study identify metabolites and metabolic pathways which could be targeted for therapeutic benefit to preserve heart quality during perfusion or provide novel biomarkers of DCD heart quality for transplant decision-making.

“We are very excited by the data coming out of the study we performed with our partners at MGH. We believe that this is another example of how metabolomics coupled with the Olaris CEREBRO platform can be used to benefit patients, expand access to lifesaving treatments, and allow for better treatment decisions and outcomes,” said Dr. Elizabeth O’Day, CEO and Founder of Olaris.

For more information on the ATC meeting or to view the Olaris presentation during the conference, visit https://atcmeeting.org/. The presentation will be made available on Olaris’ website at http://www.myolaris.com/news following the conference.

About Olaris

Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline of myOLARIS™ precision diagnostics. To learn more, visit https://www.myolaris.com/

Share article on social media or email:

Health

Dr. Gary Frishman of Boston IVF Named A 2023 Top Fertility Doctor in Rhode Island

Leave a comment


“For over 30 years, Dr. Frishman has been recognized by his peers and respected by his patients for delivering a sustained level of superior reproductive care.” — David Stern, CEO of the Boston IVF fertility network.


PROVIDENCE, R.I. (PRWEB)

Boston IVF, a worldwide leader of fertility treatment and family building, is pleased to announce that reproductive endocrinologist Gary N. Frishman, MD(he/him) has been selected by Rhode Island Monthly as a 2023 Top Fertility Doctor in Rhode Island.

Dr. Frishman has been named a Top Fertility Doctor in every Rhode Island Monthly’s Top Doctor article since the award’s inception in 1992.

Rhode Island Monthly’s Top Doctors are elected through a highly competitive peer selection process, with Rhode Island licensed physicians and clinicians selecting the most experienced, trustworthy, and empathetic candidates across 50 specialties.

Dr. Frishman, a double board-certified reproductive endocrinologist at Boston IVF, treats individuals and couples alongside fellow reproductive endocrinologist Kerri Luzzo, MD at the fertility network’s new, state-of-the-art IVF center in Providence, RI (148 W River Street #6).

Boston IVF’s new fertility center in Providence offers 10,000+ square feet of treatment space, on-site IVF, IUI, egg freezing, cycle monitoring, and more.

“Having children is one of the greatest privileges and experiences in life,” said Dr. Frishman. “I chose this field to help my patients achieve this dream.”

Alongside his Rhode Island Monthly recognition, Dr. Frishman has earned national and international acknowledgment for his contributions to Women’s Health. He has received numerous teaching awards from Brown University, the American College of Obstetricians and Gynecologists (ACOG), the Council on Resident Education in Obstetrics and Gynecology (CREOG), and the Association of Professors of Gynecology and Obstetrics (APGO), amongst others.

“For over 30 years, Dr. Frishman has been recognized by his peers and respected by his patients for delivering a sustained level of superior reproductive care,” said David Stern, CEO of the Boston IVF fertility network.

Dr. Frishman is an active member in several surgical societies —including the American Society for Reproductive Medicine (ASRM) — and served as president for both the Society for Reproductive Surgeons and the American Association of Gynecologic Laparoscopists (AAGL). Furthermore, he has held positions for internationally renowned journals such as The Obstetrician and Gynaecologist and the Journal of Minimally Invasive Gynecology.

A long-time Rhode Island resident, Dr. Frishman is also a Clinical Professor of OB/GYN at Brown University’s Warren Alpert Medical School, where he teaches the next generation of fertility doctors. Additionally, he has served on the boards of Big Sisters of Rhode Island, Day One Rhode Island, City Year Providence, and Rhode Island Blood Center’s Advocacy Board.

To learn more about Dr. Frishman, to receive fertility treatment advice, or to schedule a consultation, visit Boston IVF’s website for more information.

Follow Boston IVF on Instagram

Follow Boston IVF on Linkedin

Follow Boston IVF on Facebook

Follow Boston IVF on Twitter

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Share article on social media or email:



Health

OneStaff Medical Welcomes New Chief Financial Officer, Mike Vaughn

Leave a comment


We are beyond excited to put a proven leader, like Mike, in a position to further evolve what we are doing here


OMAHA, Neb. (PRWEB)

OneStaff Medical, an independently-owned, Omaha-based travel nurse staffing agency, recently hired Mike Vaughn in a new Chief Financial Officer (CFO) role.

Vaughn, with over 25 years of finance and business experience with a heavy focus on international operations, is being tasked with leading their finance department and evolving its operations to meet the demand from the previous couple years of rapid growth. Vaughn’s vision is to help position the company for continued success in the competitive Travel Nurse Staffing industry.

“We are beyond excited to put a proven leader, like Mike, in a position to further evolve what we are doing here,” Andrew Wettengel, Director of Marketing, said. “With his extensive experience within Finance, and successful track record, he is an obvious fit to enhance our ability to drive the next stage of our company’s growth in that department.”

OneStaff Medical provides temporary staffing solutions for healthcare facilities across the country. The 2023 year will be a pivotal year for the industry, in an already competitive marketplace, as pay rates and market fluctuations are leveling back out post COVID, “Travel Nursing Payrate Predictions for 2023”. The COVID crisis has only helped further solidify agencies, like OneStaff, as crucial staffing partners to healthcare facilities across the country.

About OneStaff Medical

Headquartered in Omaha, OneStaff Medical was founded in 2010 as a Travel Nursing staffing firm and has consistently been honored as one of SIA’s “Best Staffing Firms to Work For,” as well as made the “2022 Fastest-Growing US Staffing Firms” list. In the past few years, OneStaff also added Eldercare, Allied, and Surgery travel staffing divisions to their portfolio of services. In addition to their Omaha office, they opened a Columbus, OH office in 2020, as well as a Clearwater, FL office in 2021, and continue to look towards expanding as one of the few proudly independently-owned Travel Nurse staffing firms in the country.

Share article on social media or email:

Health

Boston IVF Welcomes Reproductive Endocrinologist Dr. Jill Attaman to Expanding New Hampshire Fertility Center Physician Team

Leave a comment


“New Hampshire patients and Boston IVF have gained an accomplished and dedicated reproductive endocrinologist in Dr. Attaman.” — David Stern, CEO of the Boston IVF fertility network.


BEDFORD, N.H. (PRWEB)

Boston IVF, one of the world’s most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986 and is known for achieving high IVF success rates, is pleased to announce the addition of reproductive endocrinologist, Jill Attaman, MD to its practice and physician team. Dr. Attaman is now accepting new patients at Boston IVF’s fertility center in Bedford, New Hampshire.

Boston IVF’s fertility center in New Hampshire, the only IVF center in the state, hosts a state-of-the-art embryology laboratory, 15,000+ square feet of treatment space, and an enhanced team dedicated to superior patient care.

Dr. Attaman specializes in a comprehensive array of infertility treatments and family building services, including, intrauterine insemination (IUI), in vitro fertilization (IVF), egg freezing, LGBTQ+ family building services, recurrent pregnancy loss, PCOS, and more.

A long-time staple of fertility treatment and care in New England, Dr. Attaman arrives at Boston IVF from a prestigious Downtown Boston hospital, where as Director of the IVF Unit, she led the organization’s assisted reproductive care program, acted as Chair of Quality Assurance for the Division of Reproductive Endocrinology and Infertility (REI), and guided its OB/GYN transgender healthcare efforts.

“I am thrilled to join a practice as renowned as Boston IVF, where I can help provide family building treatments to a New Hampshire community which deserves local access to high-quality care,” said Dr. Jill Attaman. “My patient care philosophy aligns perfectly with Boston IVF, which values respect, empathy, support, education, and so much more.”

Alongside her role as a fertility doctor, Dr. Attaman has served as an assistant professor at the Geisel School of Medicine at Dartmouth College in Hanover, NH and is a clinical instructor at Harvard Medical School.

“New Hampshire patients and Boston IVF have gained an accomplished and dedicated reproductive endocrinologist in Dr. Attaman,” said David Stern, CEO of the Boston IVF fertility network. “We’re excited to be able to add Dr. Attaman to our outstanding clinical team in Bedford. Individuals and couples throughout New Hampshire who wish to build a family through fertility and family building treatments now have yet another amazing fertility expert whom they may turn to for care.”

Double-board certified in OB/GYN and REI, Dr. Attaman earned her medical degree at Michigan State University, completed her residency in Obstetrics and Gynecology at The Ohio State University Medical Center, and received her fellowship in Reproductive Endocrinology at Massachusetts General Hospital.

To learn more about Dr. Attaman, to receive fertility treatment advice, or to schedule a consultation, visit Boston IVF’s website for more information.

Follow Boston IVF on Instagram

Follow Boston IVF on Linkedin

Follow Boston IVF on Facebook

Follow Boston IVF on Twitter

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Share article on social media or email: